View this webinar by industry specialists Xtalks to discover how to run Organ-on-a-Chip studies in your own lab to enhance research. The webinar covers: Walkthrough of an Organ-on-Chip workflow: lab set-up, seeding and culturing cells, dosing, sampling and analysis Practical advice and resources to support successful Organ-on-a-Chip studies: equipment, cell selection, protocols, assays and data… Read more »
News
Filter: Business Posts
Posted
CN Bio MicroMix to be featured at AACR
Dr David Hughes, Chief Technical Officer at Organ-on-Chip specialist CN Bio Innovations will be presenting a poster at the American Association for Cancer Research Annual Meeting 2018. The poster will cover the company’s MicroMix technology. MicroMix uses pumps and valves to, precisely control and vary with time, the concentration of drug within each well of… Read more »
Posted
PharmaVentures Interview: Will Organ-on-Chip technology provide the data Regulators need in the future?
As new drug treatments are developed, quicker and much more precise technology which predicts the effect these chemical and biological substances have on human organs are also becoming available. These technologies will be important particularly for pharmaceutical and biotech companies as they look towards the future. Will these companies continue be able to stand in… Read more »
Posted
R&D 100 Award won by Vanderbilt team for tech being developed with CN Bio
A cell-culture technology now being developed by London biotech CN Bio Innovations and its global pharmaceutical company partner, has won one of the scientific world’s premier awards – known as the “Oscars of Innovation”. A team of Vanderbilt University scientists and engineers led by Professor John P. Wikswo won the R&D 100 Award for their… Read more »
Posted
MIT and CN Bio to showcase world’s first 7 organ “Human-on-a-Chip” at Organ-On-Chip congress
MIT and CN Bio Innovations today announced that the world’s first 7-organ “Human-on-a-Chip” platform will be showcased at the Organ-on-Chip congress in Boston on the 7th and 8th of July 2016. Under a $26M Defense Advanced Research Projects Agency (DARPA) contract awarded to researchers at the Massachusetts Institute of Technology, Continuum LLC and CN Bio… Read more »
Posted
CN Bio Sponsors the Organ-On-Chip world congress in Boston
CN Bio Innovations Ltd, an expert in developing human organs-on-chips to test and develop therapeutics for serious diseases, is proud to be the platinum sponsor of SelectBio’s 2nd Annual Organ-on-a-Chip world Congress in Boston on the 7th and 8th of July. The conference brings together the world’s leading experts in Organ-on-chip technology from academia and… Read more »
Posted
CN Bio appoints Emma Sceats as CEO
CN Bio Innovations are delighted to announce the appointment of Dr Emma Sceats as Chief Executive effective 1st January 2016. Dr David Scales will remain on the board as an advisor to the company with particular emphasis on new business opportunities.
Posted
Imperial College London to present HBV data on CN Bio immune-competent liver model at AASLD The Liver Meeting
CN Bio Innovations Ltd, an expert in developing human organ chip platforms to test and develop therapeutics for serious diseases, has announced that new data from its research collaboration with Imperial College London, where the team are analysing a novel human, full-viral-lifecycle model of Hepatitis B, will be presented in the late-breaking poster session at The Liver Meeting® 2015, San Francisco USA (13-17 November, 2015).
Posted
CN Bio appoints Dr David Hughes to board of directors
Dr David Hughes has been appointed to the board of directors, effective immediately. He will also continue with his responsibility for overseeing management of all technical projects and alliances with CN Bio partners as well as managing the internal scientific and engineering teams.
Posted
CN Bio Innovations features in Al Jazeera documentary “The Cure”
CN Bio Innovations, an expert in developing human organ-on-a-chip platforms, was featured in the 10 August 2015 broadcast of The Cure, an Al Jazeera network (AJN) documentary which looks at some of the world’s most intractable health problems.
Posted
CN Bio Innovations announces deal with sixth pharmaceutical collaborator in 2015 and features in The Economist
CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is featured prominently in an article in the 13 June 2015 edition of The Economist. Simultaneous with the publication, CN Bio is pleased to announce that it has embarked on a joint research collaboration with a sixth pharmaceutical company since March 2015. The research will be based on CN Bio’s Quantum-B® model of Hepatitis B infection and leverage CN Bio’s expertise in cell culture and disease modelling.
Posted
CN Bio Innovations announces LiverChip research study with leading pharmaceutical company
CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research study with a fourth pharmaceutical company.
The program will take advantage of CN Bio’s human liver-on-a-chip platform, LiverChip, to study targets implicated in liver disease.
Posted
CN Bio Innovations announces Hepatitis B research collaboration with leading pharmaceutical company
Welwyn Garden City, UK, 21st April 2015: CN Bio Innovations, an expert in developing human organ-on-a-chip platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with a third (undisclosed) pharmaceutical company. The research, which will take advantage of CN Bio’s full viral lifecycle… Read more »
Posted
CN Bio announces research collaboration with antisense discovery pioneers Isis Pharmaceuticals
CN Bio Innovations, an expert in developing human biomimetic platforms to test and develop therapeutics for liver diseases and infection, is pleased to announce the commencement of a research collaboration with RNA based drug discovery and development company Isis Pharmaceuticals Inc. Research relevant to Isis’s innovative RNA targeting, antisense oligonucleotides will be performed at CN… Read more »
Posted
CN Bio hosts popular Investigator Meeting and presents new HBV data at AASLD 2014
CN Bio Innovations’ (CN Bio) Investigator Meeting entitled “Hepatitis B: New models pave the way to a cure” was held on Monday 10th November 2014 at the 65th AASLD Annual Meeting. The event, which was oversubscribed, focused on the need for new pre-clinical models for the study of hepatitis B and discovery of new therapeutics… Read more »
Posted
NIH Director highlights LiverChip in Compton Lecture
Dr Francis S. Collins, Director of the US National Institutes of Health (NIH), highlighted LiverChip during the 2014 Karl Taylor Compton Lecture on October 28 at the Massachusetts Institute of Technology. In his lecture entitled “Exceptional Opportunities in Biomedical Research” Collins featured work by MIT Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering… Read more »
Posted
TSB Funds New Research by CN Bio into Fatty Liver Disease
CN Bio Innovations (CN Bio) announced today the receipt of a 12 months funding award from the UK’s Technology Strategy Board (TSB) for the development of human in vitro models of Non-Alcoholic Fatty Liver Disease (NAFLD). CN Bio will partner on the award with UK-based CRO Xenogesis Ltd., which specialises in preclinical DMPK, quantitative bioanalysis… Read more »
Posted
Promotion of Dr David Hughes to the role of Chief Technology Officer
Dr David Hughes has been promoted to the role of Chief Technology Officer, effective immediately. In his new role, he will take responsibility for overseeing management of all technical projects and alliances with CN Bio partners. He will also continue to manage the internal scientific and engineering teams. Dr Hughes joined the Company in 2010… Read more »
Posted
CN Bio appoints Professor Mark Thursz as Scientific Advisor
CN Bio Innovations (CN Bio) today announced the appointment of Professor Mark Thursz as a scientific advisor to the company. “Mark has considerable experience and a deep knowledge of clinical hepatology and related non-clinical research and I believe that CN Bio will benefit from having access to Mark’s expertise as we continue to develop and… Read more »
Posted
CN Bio hires Director of Licensing
CN Bio Innovations (CN Bio) announced today the appointment of Gavin Clark to the role of Director of Licensing. This is a new position created to facilitate the commercialization of CN Bio’s novel proprietary infectious disease models. Gavin brings with him over 35 years of experience in the pharmaceutical industry including roles as Global Licensing… Read more »
Update: News
- Press releases
- 22 November 2018
- PhysioMimix™ Human 3D Cell Culture wins Lab Innovation 2018 Award
- Press releases
- 19 July 2018
- CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
Meet Us: Events
- 9-10 Oct 2018
- ELRIG Drug Discovery 2018
- London, UK
- 31 OCT - 1 NOV 2018
- Lab Innovation 2018
- Birmingham, UK
- 5 - 7 NOV 2018
- BioEurope
- Copenhagen, Denmark